Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11287053rdf:typepubmed:Citationlld:pubmed
pubmed-article:11287053lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:11287053lifeskim:mentionsumls-concept:C1522384lld:lifeskim
pubmed-article:11287053lifeskim:mentionsumls-concept:C0019903lld:lifeskim
pubmed-article:11287053pubmed:issue1lld:pubmed
pubmed-article:11287053pubmed:dateCreated2001-4-5lld:pubmed
pubmed-article:11287053pubmed:abstractTextPlasma homovanillic acid (pHVA) concentrations are considered to reflect, in part, central dopamine metabolism and thus may be of value in assessing the role of dopamine neurotransmission in schizophrenia. Furthermore, some recent studies have suggested a relationship of pHVA with symptomatology. We have undertaken a study of pHVA in a large cohort of unmedicated DSM-IV schizophrenic patients in order to assess the relationship of pHVA to various clinical parameters. pHVA in 58 drug-free patients (10.11+/-0.52 ng/ml) was significantly elevated in comparison with 62 matched control subjects (8.77+/-0.39 ng/ml). pHVA was found to be higher in patients with a more negative syndrome. No significant correlation of pHVA with overall SAPS or SANS scores was apparent in the patients although, within the SANS subscales, a significant relationship to anhedonia-asociality was apparent. Interestingly, the male drug-free patients showed a correlation of pHVA with negative symptoms defined by SANS and several SANS subscales, while females showed no significant relationship with any SANS subscales. The results may suggest that an increased dopaminergic turnover is apparent in (male) schizophrenic patients with predominantly negative symptoms, providing some support for reports that this change in neuronal activity may be related to the neuropathological abnormalities seen in the disease, which may themselves differ between males and females. Such neuronal deficits of developmental or degenerative origin may thus result in an elevation/disinhibition of central dopamine metabolism in schizophrenia.lld:pubmed
pubmed-article:11287053pubmed:languageenglld:pubmed
pubmed-article:11287053pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11287053pubmed:citationSubsetIMlld:pubmed
pubmed-article:11287053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11287053pubmed:statusMEDLINElld:pubmed
pubmed-article:11287053pubmed:issn0022-3956lld:pubmed
pubmed-article:11287053pubmed:authorpubmed-author:ReynoldsG PGPlld:pubmed
pubmed-article:11287053pubmed:authorpubmed-author:PeetMMlld:pubmed
pubmed-article:11287053pubmed:authorpubmed-author:ShahSSlld:pubmed
pubmed-article:11287053pubmed:authorpubmed-author:ZhangZ JZJlld:pubmed
pubmed-article:11287053pubmed:authorpubmed-author:RamchandC NCNlld:pubmed
pubmed-article:11287053pubmed:issnTypePrintlld:pubmed
pubmed-article:11287053pubmed:volume35lld:pubmed
pubmed-article:11287053pubmed:ownerNLMlld:pubmed
pubmed-article:11287053pubmed:authorsCompleteYlld:pubmed
pubmed-article:11287053pubmed:pagination23-8lld:pubmed
pubmed-article:11287053pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:meshHeadingpubmed-meshheading:11287053...lld:pubmed
pubmed-article:11287053pubmed:articleTitlePlasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex.lld:pubmed
pubmed-article:11287053pubmed:affiliationDepartment of Biomedical Science, University of Sheffield, S10 2TN, Sheffield, UK. g.p.reynollds@sheffield.ac.uklld:pubmed
pubmed-article:11287053pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11287053lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11287053lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11287053lld:pubmed